Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
1.0600 -0.0300 (-2.75%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 1.0600 unch (unch) 19:58 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0300
Day High
1.0800
Open 1.0800
Previous Close 1.0900 1.0900
Volume 230,200 230,200
Avg Vol 545,410 545,410
Stochastic %K 74.50% 74.50%
Weighted Alpha -59.33 -59.33
5-Day Change +0.0967 (+10.04%) +0.0967 (+10.04%)
52-Week Range 0.8332 - 5.3899 0.8332 - 5.3899
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,133
  • Shares Outstanding, K 61,590
  • Annual Sales, $ 16,150 K
  • Annual Income, $ -77,330 K
  • EBIT $ -69 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.17
  • Price/Sales 4.12
  • Price/Cash Flow N/A
  • Price/Book 0.53

Options Overview Details

View History
  • Implied Volatility 562.02% ( +298.14%)
  • Historical Volatility 97.97%
  • IV Percentile 96%
  • IV Rank 62.71%
  • IV High 889.90% on 03/17/25
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,713
  • Open Int (30-Day) 4,790

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.32
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -383.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8332 +27.22%
on 04/07/25
Period Open: 1.1500
1.1700 -9.40%
on 03/26/25
-0.0900 (-7.83%)
since 03/25/25
3-Month
0.8332 +27.22%
on 04/07/25
Period Open: 1.6000
1.6700 -36.53%
on 01/31/25
-0.5400 (-33.75%)
since 01/24/25
52-Week
0.8332 +27.22%
on 04/07/25
Period Open: 4.3000
5.3899 -80.33%
on 11/11/24
-3.2400 (-75.35%)
since 04/25/24

Most Recent Stories

More News
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

PYXS : 1.0600 (-2.75%)
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

For Immediate ReleaseChicago, IL – April 24, 2025 – Today, Zacks Equity Research discusses Aurinia Pharmaceuticals AUPH, Heron Therapeutics HRTX, Esperion Therapeutics ESPR, Pyxis Oncology PYXS and...

ESPR : 0.9200 (+4.39%)
PSTV : 0.7879 (-6.50%)
PYXS : 1.0600 (-2.75%)
AUPH : 8.18 (+0.99%)
HRTX : 2.30 (+1.32%)
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

PYXS : 1.0600 (-2.75%)
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

PYXS : 1.0600 (-2.75%)
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PYXS : 1.0600 (-2.75%)
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

PYXS : 1.0600 (-2.75%)
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

PYXS : 1.0600 (-2.75%)
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

PYXS : 1.0600 (-2.75%)
Pyxis Oncology Prioritizes Development of Lead Asset PYX-201 Following Promising Phase 1 Results

Pyxis Oncology prioritizes development of PYX-201, an antibody-drug conjugate showing promise in treating solid tumors, including HNSCC.Quiver AI SummaryPyxis Oncology, Inc. is reallocating its resources...

PYXS : 1.0600 (-2.75%)
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

PYXS : 1.0600 (-2.75%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.1333
2nd Resistance Point 1.1067
1st Resistance Point 1.0833
Last Price 1.0600
1st Support Level 1.0333
2nd Support Level 1.0067
3rd Support Level 0.9833

See More

52-Week High 5.3899
Fibonacci 61.8% 3.6492
Fibonacci 50% 3.1116
Fibonacci 38.2% 2.5739
Last Price 1.0600
52-Week Low 0.8332

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective